Predictores de riesgo en una cohorte española con cardiolaminopatías. Registro REDLAMINA

[1]  J. Ochoa,et al.  Letter by Barriales-Villa et al Regarding Article, "Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies". , 2019, Circulation.

[2]  R. Porcher,et al.  Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. , 2019, Circulation.

[3]  E. Arbustini,et al.  Lamin mutation location predicts cardiac phenotype severity: combined analysis of the published literature , 2018, Open Heart.

[4]  E. Arbustini,et al.  Lamin missense mutations—the spectrum of phenotype variability is increasing , 2018, European journal of heart failure.

[5]  Y. Pinto,et al.  The clinical outcome of LMNA missense mutations can be associated with the amount of mutated protein in the nuclear envelope , 2018, European journal of heart failure.

[6]  William J. Bryant,et al.  2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.

[7]  A. Wilde,et al.  Lamin A/C-Related Cardiac Disease: Late Onset With a Variable and Mild Phenotype in a Large Cohort of Patients With the Lamin A/C p.(Arg331Gln) Founder Mutation , 2017, Circulation. Cardiovascular genetics.

[8]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[9]  A. Zwinderman,et al.  Gender‐specific differences in major cardiac events and mortality in lamin A/C mutation carriers , 2013, European journal of heart failure.

[10]  A. Zwinderman,et al.  Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. , 2012, Journal of the American College of Cardiology.

[11]  I. V. Van Gelder,et al.  High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. , 2007, American heart journal.

[12]  Y. Pinto,et al.  Primary prevention of sudden death in patients with lamin A/C gene mutations. , 2006, The New England journal of medicine.

[13]  L. Mestroni,et al.  Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. , 2003, Journal of the American College of Cardiology.

[14]  Eloisa Arbustini,et al.  Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. , 2002, Journal of the American College of Cardiology.

[15]  William J. Bryant,et al.  Practice Guideline: Executive Summary2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines , 2017 .

[16]  H. Crijns,et al.  Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? , 2004, Journal of Molecular Medicine.